The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
This content originally appeared on our sister site, CancerNetwork®.
CancerNetwork® spoke with Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, at the 2021 American Society of Clinical Oncology Annual Meeting, about the numerous trials that read out at the meeting pertaining to CAR T-cell therapy in patients with hematologic malignancies. Vose discusses the benefit of this therapy for patients with follicular lymphoma in addition to how it may affect patients with other lymphomas.
[One category that really excites me is] the use of CAR T-cells for other types of lymphomas other than diffuse large B-cell. There were a couple of different trials that were presented [at ASCO] looking at CAR T-cells for follicular lymphoma. That has shown some follow up information, and we can see that those specific types of CAR T-cells now can be applied to other types of lymphomas and have some good outcomes. We are looking forward to applying that [technology] to other types of lymphomas, as well as other malignancies.